Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Fisons |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002055 |
To evaluate and compare the safety, tolerability, and effectiveness of long-term biweekly administration of 1 of 2 doses of aerosol pentamidine when used as a
prophylactic agent in patients who have had multiple episodes of AIDS associated Pneumocystis carinii pneumonia (PCP).
Condition | Intervention |
---|---|
Pneumonia, Pneumocystis Carinii HIV Infections |
Drug: Pentamidine isethionate |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind |
Official Title: | A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Concurrent Medication:
Excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 30 days of study entry:
Prior Treatment:
Excluded within 7 days of study entry:
Active substance abuse.
United States, District of Columbia | |
Veterans Administration Med Ctr | |
Washington, District of Columbia, United States, 20422 | |
Georgetown Univ | |
Washington, District of Columbia, United States, 20007 | |
United States, Illinois | |
Northwestern Univ Med School | |
Chicago, Illinois, United States, 60611 | |
United States, Massachusetts | |
Beth Israel Deaconess - West Campus | |
Boston, Massachusetts, United States, 02215 |
Study ID Numbers: | 022D, 88-7 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002055 History of Changes |
Health Authority: | United States: Food and Drug Administration |
AIDS-Related Opportunistic Infections Pneumonia, Pneumocystis carinii Pentamidine |
Dose-Response Relationship, Drug Aerosols Acquired Immunodeficiency Syndrome |
Anti-Infective Agents Opportunistic Infections Sexually Transmitted Diseases, Viral Pneumocystosis Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Virus Diseases Mycoses Pneumonia, Pneumocystis Pneumocystis Infections Respiratory Tract Infections |
Respiratory Tract Diseases HIV Infections Antifungal Agents Lung Diseases AIDS-Related Opportunistic Infections Sexually Transmitted Diseases Pentamidine Retroviridae Infections Pneumonia Lung Diseases, Fungal |
Trypanocidal Agents Anti-Infective Agents Antiprotozoal Agents Sexually Transmitted Diseases, Viral Slow Virus Diseases Infection Pneumonia, Pneumocystis Mycoses Antiparasitic Agents Respiratory Tract Diseases Respiratory Tract Infections Antifungal Agents Therapeutic Uses Pentamidine |
Retroviridae Infections Lung Diseases, Fungal RNA Virus Infections Immune System Diseases Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Pharmacologic Actions Virus Diseases Pneumocystis Infections HIV Infections Lung Diseases Sexually Transmitted Diseases Lentivirus Infections Pneumonia |